Condition evidence map
HIV-associated lipodystrophy
Research evidence map for HIV-associated lipodystrophy: tesamorelin (Egrifta) as the US-licensed GHRH analogue for excess visceral adipose tissue in HIV.
Research context
Lipodystrophy is a recognised long-term complication of certain HIV antiretroviral regimens. Tesamorelin, a synthetic GHRH analogue, is the US FDA-approved therapy (Egrifta) for excess visceral adiposity in HIV-associated lipodystrophy.
Why this matters metabolically
Outside the obesity / T2D mainstream, HIV-associated lipodystrophy is the principal licensed indication for a peptide acting on the growth-hormone axis specifically for body-fat distribution.
FAQs
- Is tesamorelin available in the UK?
- Tesamorelin (Egrifta) is US FDA-approved for HIV-associated lipodystrophy but is not currently MHRA-licensed in the UK. UK access requires jurisdiction-specific clinical pathways.
- Tesamorelin's licensed indication is HIV-associated lipodystrophy specifically, not generic obesity.
- Growth-hormone-axis therapies have a different safety profile from incretin medicines and should not be cross-promoted.
Related mechanisms
Related peptide profiles
Related trials
No published trials yet linked to this page. Source verification required.
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site